Skip to main content
Livermore
Livermore
ZHEN

Schonfeld Strategic Advisors LLC

SEC CIK
0001665241
Latest filing
Aug 14, 2026

The latest 13F from Schonfeld Strategic Advisors LLC covers Q2 2026 (filed Aug 14, 2026): 2,292 long positions worth $18.9B. The top 10 holdings make up 30.0% of the portfolio, and the largest is iShares Core S&P 500 ETF at 15.2%. Livermore has 23 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
868
Est. +$3.32B
Added
728
Est. +$6.73B
Reduced
620
Est. −$4.00B
Sold out
615
Est. −$1.42B

Top 5 holdings

Share of this quarter's portfolio value

  1. iShares Core S&P 500 ETF464287200
    15.2%$2.87B
  2. MUMicron Technology Inc
    3.5%$655.7MHistory
  3. NVDANVIDIA Corp
    2.6%$491.7MHistory
  4. MSFTMicrosoft Corp
    1.8%$341.4MHistory
  5. iShares Inc464286400
    1.7%$323.1M

Share of portfolio

Top 5 holdings and the other 2,287 positions, by share of portfolio value

  1. iShares Core S&P 500 ETF15.2%
  2. MU3.5%
  3. NVDA2.6%
  4. MSFT1.8%
  5. iShares Inc1.7%
  6. Other 2,287 positions75.3%

Biggest buys

New and added positions, by estimated amount bought

  1. iShares Core S&P 500 ETF464287200
    +$708.7MAdded
  2. NVDANVIDIA Corp
    +$462.1MAddedHistory
  3. iShares Inc464286400
    +$323.1MNew
  4. MSFTMicrosoft Corp
    +$319.9MAddedHistory
  5. GOOGLAlphabet Inc.
    +$260.2MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. NVDANVIDIA Corp
    +2.39 pp0.2% → 2.6%History
  2. MUMicron Technology Inc
    +2.13 pp1.3% → 3.5%History
  3. iShares Inc464286400
    +1.71 pp0.0% → 1.7%
  4. MSFTMicrosoft Corp
    +1.63 pp0.2% → 1.8%History
  5. GOOGLAlphabet Inc.
    +1.34 pp0.2% → 1.5%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. SPYSPDR S&P 500 ETF Trust
    −$190.7MReducedHistory
  2. ARMArm Holdings PLC
    −$121.9MReducedHistory
  3. METAMeta Platforms, Inc.
    −$120.6MReducedHistory
  4. AMATApplied Materials Inc
    −$87.3MReducedHistory
  5. CRHCRH Public Ltd Co
    −$76.3MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. SPYSPDR S&P 500 ETF Trust
    −1.45 pp1.7% → 0.3%History
  2. METAMeta Platforms, Inc.
    −1.02 pp1.1% → <0.1%History
  3. CRHCRH Public Ltd Co
    −0.78 pp1.1% → 0.3%History
  4. FBTCFidelity Wise Origin Bitcoin Fund
    −0.68 pp1.2% → 0.5%History
  5. ARKBArk 21Shares Bitcoin ETF
    −0.62 pp1.0% → 0.4%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$18.9B
+$6.64B (+54.1%) vs. prior quarter
Positions
2,292
+253 vs. prior quarter
Top 10 concentration
30.0%
Top 10 as share of value
Turnover
34.7%
Q2 2026, one quarter
Average holding period
7.8 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $19.9B (Q4 2025)

Q1 2021: $7.54BQ2 2021: $8.97BQ3 2021: $8.79BQ4 2021: $10.3BQ1 2022: $8.97BQ2 2022: $9.50BQ3 2022: $11.9BQ4 2022: $12.0BQ1 2023: $10.4BQ2 2023: $11.6BQ3 2023: $10.8BQ4 2023: $12.2BQ1 2024: $12.7BQ2 2024: $12.9BQ3 2024: $12.3BQ4 2024: $15.8BQ1 2025: $14.9BQ2 2025: $13.3BQ3 2025: $14.3BQ4 2025: $19.9BQ1 2026: $12.3BQ2 2026: $18.9B
Q1 2021Q2 2026
13F filings of Schonfeld Strategic Advisors LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 20262,292$18.9BiShares Core S&P 500 ETFMUNVDAvs. Q1 2026SEC
Q1 2026May 15, 20262,039$12.3BiShares Core S&P 500 ETFSPYMUvs. Q4 2025SEC
Q4 2025Feb 17, 20261,842$19.9BiShares Core S&P 500 ETFSPYNVDAvs. Q3 2025SEC
Q3 2025Nov 14, 20251,972$14.3BSPYIBITETHAvs. Q2 2025SEC
Q2 2025Aug 14, 20251,877$13.3BSPYFBTCIBITvs. Q1 2025SEC
Q1 2025May 15, 20252,036$14.9BiShares Core S&P 500 ETFSPYFBTCvs. Q4 2024SEC
Q4 2024Feb 14, 20251,883$15.8BiShares Core S&P 500 ETFSPYFBTCvs. Q3 2024SEC
Q3 2024Nov 14, 20241,837$12.3BSPYiShares Core S&P 500 ETFFBTCvs. Q2 2024SEC
Q2 2024Aug 14, 20241,957$12.9BiShares Core S&P 500 ETFSPYInvesco QQQ Trust Series Ivs. Q1 2024SEC
Q1 2024May 15, 20241,832$12.7BSPYIBITFBTCvs. Q4 2023SEC
Q4 2023Feb 14, 20241,730$12.2BSPYFDXAMZNvs. Q3 2023SEC
Q3 2023Nov 14, 20231,571$10.8BFDXMSFTUNPvs. Q2 2023SEC
Q2 2023Aug 14, 20231,923$11.6BNVDAMSFTSHWvs. Q1 2023SEC
Q1 2023May 15, 20231,952$10.4BVBIOTSLAvs. Q4 2022SEC
Q4 2022Feb 14, 20232,460$12.0BFERGAMZNVvs. Q3 2022SEC
Q3 2022Nov 14, 20222,832$11.9BAMZNAIGEXPEvs. Q2 2022SEC
Q2 2022Aug 15, 20222,387$9.50BBIOHIGWFCvs. Q1 2022SEC
Q1 2022May 16, 20222,342$8.97BWFCHIGAJGvs. Q4 2021SEC
Q4 2021Feb 14, 20221,915$10.3BSPYBIOAJGvs. Q3 2021SEC
Q3 2021Nov 16, 20211,949$8.79BBIOWTWAJGvs. Q2 2021SEC
Q2 2021Nov 16, 2021Amended1,846$8.97BAMZNUSBSTTvs. Q1 2021SEC
Q1 2021May 17, 20211,701$7.54BTRPBNSAVTR–SEC

13D and 13G filings

Companies where Schonfeld Strategic Advisors LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

1 company, largest stake first.

Companies where Schonfeld Strategic Advisors LLC owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
INBXInhibrx Biosciences, Inc.13G5.33%781.7K sharesNewAug 14, 20261 filingAug 14, 2026SEC

Latest filings

31 filings on file made by Schonfeld Strategic Advisors LLC or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Schonfeld Strategic Advisors LLC
CompanyFiled (ET)FormStakeChangeEvent dateFiling
INBXInhibrx Biosciences, Inc.Aug 14, 20264:15 PM ET13G5.33%781.7K sharesNewJun 30, 2026SEC
CDNLCardinal Infrastructure Group Inc.May 15, 20264:15 PM ET13G/A2.88%439.7K shares−5.72 ppfrom 8.60%Below 5%Mar 31, 2026SEC
JZXNJiuzi Holdings, Inc.Feb 17, 20265:47 PM ET13G0.00%0 sharesNewBelow 5%Feb 10, 2026SEC
MRSNMersana Therapeutics, Inc.Feb 17, 20264:31 PM ET13G/A0.00%0 shares−5.48 ppfrom 5.48%Below 5%Dec 31, 2025SEC
CDNLCardinal Infrastructure Group Inc.Feb 17, 20264:30 PM ET13G8.60%1.29M sharesNewDec 31, 2025SEC
MRSNMersana Therapeutics, Inc.Nov 14, 20254:15 PM ET13G5.48%273.6K shares+0.93 ppfrom 4.55%Sep 30, 2025SEC
MRSNMersana Therapeutics, Inc.Aug 14, 20254:31 PM ET13G/A4.55%5.67M shares−1.56 ppfrom 6.11%Below 5%Jun 30, 2025SEC
SKYESkye Bioscience, Inc.Aug 14, 20254:31 PM ET13G/A3.60%1.12M shares−1.62 ppfrom 5.22%Below 5%Jun 30, 2025SEC
FATEFate Therapeutics IncAug 14, 20254:30 PM ET13G/A0.82%937.5K shares−5.98 ppfrom 6.80%Below 5%Jun 30, 2025SEC
MRSNMersana Therapeutics, Inc.May 15, 20254:31 PM ET13G6.11%7.61M sharesNewMar 31, 2025SEC
TERNTerns Pharmaceuticals, Inc.May 15, 20254:31 PM ET13G/A4.93%4.31M shares−1.23 ppfrom 6.16%Below 5%Mar 31, 2025SEC
SKYESkye Bioscience, Inc.May 15, 20254:31 PM ET13G5.22%1.62M sharesNewMar 31, 2025SEC
FATEFate Therapeutics IncMay 15, 20254:30 PM ET13G6.80%7.79M sharesNewMar 31, 2025SEC
APLTApplied Therapeutics, Inc.May 15, 20254:30 PM ET13G/A3.30%4.68M shares−4.24 ppfrom 7.54%Below 5%Mar 31, 2025SEC
RVPHReviva Pharmaceuticals Holdings, Inc.Feb 14, 20254:16 PM ET13G/A2.82%1.31M shares–Below 5%Dec 31, 2024SEC
APLTApplied Therapeutics, Inc.Feb 14, 20254:15 PM ET13G7.54%8.77M sharesNewDec 31, 2024SEC
TERNTerns Pharmaceuticals, Inc.Feb 14, 20254:15 PM ET13G/A6.16%5.23M shares–Dec 31, 2024SEC
RVPHReviva Pharmaceuticals Holdings, Inc.Nov 14, 202413GOld format–New–SEC
BGMSBio Green Med Solution, Inc.Feb 14, 202413G/AOld format–––SEC
GCMGGCM Grosvenor Inc.Feb 14, 202413G/AOld format–––SEC